Thymodepressin-Unforeseen Immunosuppressor
Deigin VI, Vinogradova JE, Vinogradov DL, Krasilshchikova MS, Ivanov VT · 2021 · Molecules (Basel, Switzerland)
Study data at a glance
- Participants or experimental model
- Small mouse autoimmunity experiments, approximately five to eight animals per group
- Reported results
- Experimental anti-fibrillarin autoantibody responses were lower in selected Thymodepressin groups, including comparisons begun after autoimmunity developed.
Molekul summary of the linked publication. Educational information, not medical advice. Seek qualified healthcare help for medical conditions.
Methods, limitations & source review
Study limitations
- Small induced-animal model, not a human lupus trial.
- Comparisons against cyclosporine do not establish clinical superiority or equivalent human exposures.
- The article combines experimental results with historical clinical discussion; those evidence types must remain separate.
Publication counts are not counts of independent trials. Reviews, translations and reports sharing participants may overlap. Findings apply to the studied preparation, population and endpoints.
Source access and review scope
Primary open-access paper checked for animal endpoints and group sizes; not a completed systematic appraisal.
Recorded source-check date: 2026-11-05. This date does not imply a completed systematic review.
Citation and original source
Original source: Deigin VI, Vinogradova JE, Vinogradov DL, Krasilshchikova MS, Ivanov VT. Thymodepressin-Unforeseen Immunosuppressor Molecules (Basel, Switzerland) 2021.
Molekul research summary: https://molekul.io/research/auto-34770959. Cite the original publication for its findings and this page when referring to Molekul’s summary or evidence appraisal.
Bibliography entry